clinical trial · NCT06952465
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Bristol-Myers Squibb·—·active not recruiting·n = 2,000
PsoriasisDeucravacitinibAny biologic treatment for psoriasis
brief summary
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
started
Jan 24, 2025
primary completion
Nov 30, 2031
completion
Nov 30, 2031
last updated
May 1, 2025
official title
A Cohort Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis Using Administrative Health Claims Database
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol